Yale University, New Haven, CT., 1986, B.A., Philosophy
Bryn Mawr College, Bryn Mawr, PA, 1988-89, Pre-medical studies
Brown University, Providence, RI, 1993, M.D., Medicine
University of Washington, Seattle, WA, 1993-97, Residency, Anatomic Pathology
University of Washington, Seattle, WA, 1996-98, Postdoctoral Fellowship, Environmental Pathology & Toxicology
Dr. Pierce is a Board-certified Anatomic Pathologist with a strong academic and industry background in immuno-oncology. His laboratory research is focused on mechanisms of tumor-induced immune tolerance by which tumors can escape anti-tumor immune responses, including natural and therapy-induced responses. He is expert in using multiparametric immunohistochemistry panels to quantitatively analyze the phenotype and tissue distribution of immune cells within the tumor microenvironment, and in the development of biomarkers to predict responses to immuno-oncology treatments. While at Merck, Dr. Pierce led a team focused on the the development of tissue-based biomarkers for Merck’s anti-PD- 1 therapeutic antibody (pembrolizumab; KEYTRUDA®) and was the medical lead responsible for kicking-off the clinical trials of pembrolizumab in Merkel cell carcinoma and mycosis fungoides.